Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre

Alison J. Potter; Andrew J. Colebatch; Robert V. Rawson; Peter M. Ferguson; Wendy A. Cooper; Ruta Gupta; Sandra O’Toole; Robyn P.M. Saw; Sydney Ch’ng; Alexander M. Menzies; Georgina V. Long; Richard A Scolyer

doi:10.1016/j.pathol.2021.12.290

Related publications

Article2014

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Samantha Bowyer, Aparna D. Rao, Megan Lyle, Shahneen Sandhu, Georgina V. Long, Grant A. McArthur, Jeanette Raleigh, Rodney J. Hicks, Michael Millward

Article2011

BRAF mutation by age-decade and body mass index in metastatic melanoma.

Alexander M. Menzies, Lydia Visintin, Mark D. Chatfield, Matteo S. Carlino, Julie R. Howle, Richard A Scolyer, John F. Thompson, Richard Kefford, Georgina V. Long

Article2010

Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.

Georgina V. Long, Alexander M. Menzies, Adnan Nagrial, Lauren E. Haydu, Anne Hamilton, Graham J. Mann, Michael Hughes, John F. Thompson, Richard A Scolyer, Richard Kefford

Article2016

BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples

Hojabr Kakavand, Trina Lum, James S. Wilmott, Elizabeth Smith, Sandra O’Toole, Georgina V. Long, Richard A Scolyer

Article2013

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

James S. Wilmott, Alexander M. Menzies, Lauren E. Haydu, David Capper, Matthias Preusser, Ying E. Zhang, John F. Thompson, Richard Kefford, Andreas von Deimling, Richard A Scolyer, Georgina V. Long